Kathmere Capital Management LLC Increases Holdings in Johnson & Johnson (NYSE:JNJ)

Kathmere Capital Management LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 1.5% in the second quarter, Holdings Channel reports. The fund owned 13,242 shares of the company’s stock after purchasing an additional 195 shares during the period. Kathmere Capital Management LLC’s holdings in Johnson & Johnson were worth $2,192,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Atlantic Private Wealth LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $32,000. GW&K Investment Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth $35,000. Dark Forest Capital Management LP raised its position in Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after purchasing an additional 188 shares during the period. Ruedi Wealth Management Inc. purchased a new position in shares of Johnson & Johnson during the 4th quarter worth $42,000. Finally, Kepos Capital LP purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $45,000. Institutional investors and hedge funds own 68.40% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider William Hait sold 14,698 shares of the firm’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $162.41 on Tuesday. The firm has a market capitalization of $422.10 billion, a PE ratio of 32.88, a price-to-earnings-growth ratio of 3.26 and a beta of 0.54. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The business’s fifty day moving average price is $166.21 and its 200 day moving average price is $161.83. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. The business had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the company earned $2.59 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.03 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were paid a dividend of $1.19 per share. The ex-dividend date was Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.93%. Johnson & Johnson’s dividend payout ratio is currently 96.36%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on JNJ shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday. Atlantic Securities lifted their target price on shares of Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a report on Friday, August 4th. HSBC initiated coverage on Johnson & Johnson in a research note on Wednesday, September 6th. They set a “hold” rating and a $175.00 price target on the stock. Credit Suisse Group increased their target price on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Finally, Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating for the company in a research note on Thursday, August 31st. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Hold” and an average price target of $170.65.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.